As mentioned in a previous post the DAX Biochips from AIM Biotech are an innovative and versatile microfluidic platform, allowing researchers to more easily develop 3D cell culture models, to work as close as possible to what occurs in the human body, but under in-vitro conditions.

Due to its innovative structure (as seen in this general AIM Chips flyer), a broad range of applications have already been validated on this model (Cellular Migration-Invasion Analysis / Angiogenesis studies / Metstasis Modeling System), but what’s new is that now Immunotherapy and T-Cell Therapy studies can be performed on this technology.

Fig 1: CD39 and CD73 leading to elevated levels of extracellular adenosine.

Extracellular adenosine 5′-triphosphate (ATP) is released by dying and damaged cells, and it acts on many immune cells to promote inflammation. On the other hand, the unphosphorylated
metabolite, adenosine, functions as an anti-inflammatory molecule. Two extracellular ecto-5´-Nucleotidases, CD39, and CD73, convert extracellular ATP to ADP/AMP and AMP to adenosine, respectively, leading to elevated levels of extracellular adenosine (Fig 1).